<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00401427</url>
  </required_header>
  <id_info>
    <org_study_id>HERVIN</org_study_id>
    <nct_id>NCT00401427</nct_id>
  </id_info>
  <brief_title>HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer</brief_title>
  <official_title>A Single-centre Phase 2 Study of Vinorelbine Plus 3-weekly Trastuzumab in Metastatic Breast Cancer Overexpressing Her-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <brief_summary>
    <textblock>
      The combination of vinorelbine with weekly trastuzumab has produced high response rate in
      HER2 overexpressing metastatic breast cancer (MBC). The present phase 2 study was planned to
      test activity of the same combination, with trastuzumab given every 3 weeks, rather than
      weekly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The schedule of treatment includes vinorelbine (30 mg/m2 on days 1 &amp; 8 every 21 days) and
      trastuzumab (8 mg/kg on day 1 and then 6 mg/kg every 21 days). Vinorelbine is planned for
      maximum 9 cycles, while trastuzumab can be continued until progression. This study is a
      single-stage phase 2 design, and patients eligible for response evaluation are required.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
  </secondary_outcome>
  <enrollment>50</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed breast cancer

          -  Stage IV

          -  No prior or not more than one prior chemotherapy for metastatic disease

          -  Overexpression of HER-2 (3+ on immunohistochemical exam) or amplified genetic
             expression of c-erbB2/neu (positive by Fish method)

          -  Performance status 0-2 (ECOG)

        Exclusion Criteria:

          -  Absence of measurable disease

          -  Life expectancy &lt; 3 months

          -  Concomitant malignancy or malignancy within previous 5 years (except basal cell or
             spinocellular skin cancer and in situ cervical cancer if they have been adequately
             treated

          -  Previous treatment with trastuzumab or vinorelbine

          -  Neutrophils &lt; 1500/mm3 or platelets &lt; 100000/mm3 or haemoglobin &lt; 8 g/dl

          -  Creatinine &gt; 1.5 x the value of the upper normal limit

          -  GOT and/or GPT &gt; 2.5 x the value of the upper normal limit and/or bilirubin &gt; 1.5 x
             the value of the upper normal limit in the absence of liver metastases

          -  GOT and/or GPT &gt; 5 x the value of the upper normal limit and/or bilirubin &gt; 3 x the
             value of the upper normal limit in the presence of liver metastases

          -  Left ventricular ejection fraction &lt; 50% (measured by ultrasound or MUGA angiography)

          -  Concomitant conditions that contraindicate the use of the drugs in the protocol

          -  Male gender

          -  Pregnancy or lactationÂ·

          -  Incapacity or refusal to provide informed consent

          -  Inability to comply with followup
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea De Matteis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples, Division of Medical Oncology C</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples, Clinical Trials Unit</affiliation>
  </overall_official>
  <results_reference>
    <citation>De Maio E, Pacilio C, Gravina A, Morabito A, Di Rella F, Labonia V, Landi G, Nuzzo F, Rossi E, Silvestro P, Botti G, Di Bonito M, Curcio MP, Formichelli F, La Vecchia F, Staiano M, Maurea N, D'Aiuto G, D'Aiuto M, Thomas R, Signoriello G, Perrone F, de Matteis A. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial. BMC Cancer. 2007 Mar 20;7:50.</citation>
    <PMID>17374151</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2006</study_first_submitted>
  <study_first_submitted_qc>November 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2006</study_first_posted>
  <last_update_submitted>July 12, 2012</last_update_submitted>
  <last_update_submitted_qc>July 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2 overexpression</keyword>
  <keyword>combination therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

